EGFR Resisters Patient Portal

Stay informed and get involved in EGFR programs, patient groups, and clinical trials.

Webinar Series

This 3-part webinar series will help you gain a better understanding of the science and language involved in EGFR NSCLC testing and strategies to help lead to better outcomes.

Presenters

Joshua Bauml, MD and Melina Marmarelis, MD, MSCE

Webinar 1

Progression. Now What? Necessary Testing, Common Mechanisms of EGFR-Dependent Resistance, and Possible Treatment Strategies

Review necessary biomarker testing that should be conducted upon disease progression.
Consider the pros/cons of liquid biopsy.
Discuss common mechanisms of EGFR‐dependent resistance (e.g., C797S) that occur on 1st and 2nd generation EGFR TKI therapies, including osimertinib.
Explore treatments and clinical trials that may offer benefit for progression from common EGFR‐ dependent post‐osimertinib mutations.
Weigh treatment considerations if CNS disease is still under control on osimertinib.

Download Handout

Presenters

Zofia Piotrowska, MD and Catherine Meador, MD, PhD

Webinar 2

I Have Another Oncogene Driver! What Are the Implications of This?

Outline other oncogene driver mutations that may be found upon progression (e.g., MET amplification, RET fusion, BRAF, HER2, etc.).
Explore treatments and clinical trials that may offer benefit for progression associated with secondary, non‐EGFR driver mutations.

Download Handout

Presenters

Helena A. Yu, MD and Joseph Chan, MD, PhD

Webinar 3

What is Histological Transformation, and Can it Be Treated?

Discuss histological transformations that may occur after treatment with EGFR TKIs, including small cell and squamous cell.
Explore treatments and clinical trials that may offer benefit for progression associated with histological transformation.

Download Handout

Meet the Moderators

Ivy Elkins

In Memoriam

Ivy Elkins was diagnosed at age 47 with EGFR-positive stage IV lung cancer that had metastasized to her bones and brain. Ivy had been treated successfully with targeted therapy medications since her diagnosis, thus allowing her to lead an active life and handle her lung cancer as a chronic disease. Ivy received her treatment at the University of Chicago and lived in the Chicago suburbs with her husband Ben and her two teenaged boys. Ivy earned an undergraduate degree in English from Princeton University and a Master’s in Business Administration from the Wharton School at the University of Pennsylvania.

Jill Feldman

Diagnosed 2009

My journey with lung cancer started long before I became a patient. When I was 13 years old, I lost two grandparents and my dad to lung cancer within a period of eight months. Fourteen years later, my mom and close aunt succumbed to the disease within a two-year period. I needed to find a way to redirect my anger into action so I became a volunteer and advocate for lung cancer. Then, as president of LUNGevity Foundation the unthinkable happened. In 2009, at 39 years old with four small children, I was diagnosed with lung cancer.